Metabolomics as a promising tool for improving understanding of multiple sclerosis: A review of recent advances

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that usually affects young adults. The development of MS is closely related to the changes in the metabolome. Metabolomics studies have been performed using biofluids or tissue samples from rodent models and human patients to reveal metabolic alterations associated with MS progression. This review aims to provide an overview of the applications of metabolomics that for the investigations of the perturbed metabolic pathways in MS and to reveal the potential of metabolomics in personalizing treatments. In conclusion, informative variations of metabolites can be potential biomarkers in advancing our understanding of MS pathogenesis for MS diagnosis, predicting the progression of the disease, and estimating drug effects. Metabolomics will be a promising technique for improving clinical care in MS.

Automated summary

This review provides an overview of the applications of metabolomics in studying perturbed metabolic pathways in multiple sclerosis (MS) and its potential for personalized treatments. Metabolic alterations associated with MS progression can be revealed through metabolomics, and informative variations of metabolites can serve as potential biomarkers for understanding MS pathogenesis, predicting disease progression, and estimating drug effects.